Candriam S.C.A. Black Diamond Therapeutics, Inc. Transaction History
Candriam S.C.A.
- $17.1 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding BDTX
# of Institutions
118Shares Held
48.9MCall Options Held
1.84MPut Options Held
1.93M-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.7MShares$23.9 Million0.03% of portfolio
-
Bellevue Group Ag Kuesnacht, V88.52MShares$19 Million0.62% of portfolio
-
Vestal Point Capital, LP New York, NY5.03MShares$11.2 Million1.66% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$9.92 Million1.48% of portfolio
-
Black Rock Inc. New York, NY3.22MShares$7.17 Million0.0% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $81M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...